Skip to main content

Table 2 Baseline characteristics of persons with and without incident HCC

From: Hepatocellular carcinoma occurs frequently and early after treatment in HCV genotype 3 infected persons treated with DAA regimens

Variable

With HCC (N = 42)

Without HCC

P-value

Mean age, (SD)

57.4 (8.4)

48.6 (11.3)

< 0.0001

Median age, IQR

58 (53,65)

50 (40,56)

< 0.0001

Sex, % male

45.24%

49.03%

0.63

Weight, mean (SD) kg

67.4 (13)

72.1 (13)

0.02

Obesity (% obese)

11.90%

16.93%

0.40

Hypertension, %

7.14%

6.93%

0.96

Diabetes, %

47.60%

26.90%

0.004

Hepatitis B virus coinfection

0.30%

1.06%

0.09

Cirrhosis, %

100.00%

45.97%

< 0.0001

 Cirrhosis decompensated, %

30.95%

9.35%

< 0.0001

HCV RNA, median log10 IU/mL (IQR)

6.30 (5.84,6.51)

5.87 (5.20,6.45)

0.24

HCV genotype 3

95.2

90.5

0.41

Sustained virologic response, %

87.5

92.2

0.29

Median time to HCC, weeks (IQR)

28 (21,39)

N/A

–

Treatment regimen, %

  

0.0006

 SOF/RBV/PEG-IFN

2.4

26.8

 

 SOF/RBV

71.4

61.6

 

 SOF/DCV/RBV

23.8

9.7

 

 SOF/DCV

2.4

1.9

 
  1. IQR inter-quartile range, HCC hepatocellular carcinoma, SOF sofosbuvir, RBV ribavirin, PEG-IFN pegylated interferon, DCV daclatasvir;